Libroxar (Buprenorphine, Naloxone)

Buprenorphine acts as a partial agonist at the μ‑opioid receptor, providing enough activation to lessen withdrawal while limiting euphoria. Naloxone is an opioid antagonist that is poorly absorbed sublingually but blocks opioid effects if the medication is injected, discouraging misuse.

The specific dose of Libroxar is determined by the prescribing clinician based on the individual’s medical condition, prior opioid exposure, and response to therapy. Healthcare professionals tailor the regimen to achieve optimal control of cravings and withdrawal.

Safety data for Libroxar in pregnancy and lactation are limited. Clinicians should weigh potential benefits against risks and consider alternative treatments. If used, close monitoring of both mother and infant is recommended.

To order Libroxar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with methadone, Libroxar (buprenorphine/naloxone) has a ceiling effect on respiratory depression, offering a safer profile in overdose. Its sublingual route provides flexibility, while the naloxone component reduces injection‑related abuse potential, distinguishing it from single‑agent buprenorphine products.

Libroxar should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and do not store in bathrooms or other humid environments.

Libroxar is administered sublingually. The tablet or film is placed under the tongue and allowed to dissolve completely without chewing or swallowing whole. Patients should avoid eating or drinking for at least 30 minutes after administration to ensure proper absorption.

The most serious risks include respiratory depression, severe hypotension, hepatic dysfunction, and rare cardiac arrhythmias such as QT prolongation. Patients should be monitored closely for signs of these events, especially when combined with other central nervous system depressants.

Libroxar is contraindicated in individuals with known hypersensitivity to buprenorphine, naloxone, or any formulation components. It should also be avoided in patients with acute severe respiratory depression, uncontrolled severe asthma, or those currently intoxicated with opioids.